Ramucirumab and Durvalumab for Previously Treated, Advanced NSCLC, Gastric/GEJ Adenocarcinoma, or HCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ramucirumab and Durvalumab for Previously Treated, Advanced Non-Small-Cell Lung Cancer, Gastric/Gastro-Oesophageal Junction Adenocarcinoma, or Hepatocellular Carcinoma: An Open-Label, Phase Ia/b Study (JVDJ)
Eur. J. Cancer 2020 Sep 01;137(xx)272-284, YJ Bang, T Golan, L Dahan, S Fu, V Moreno, K Park, R Geva, F De Braud, ZA Wainberg, M Reck, L Goff, N Laing, G Mi, JM Oliveira, H Wasserstrom, CC LinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.